Klebsiella pneumoniae is considered as the most common pathogen of hospital-acquired pneumonia. K. pneumoniae has emerged as the superbug which had shown multidrug resistance (MDR) as well as extensively drug resistance. Carbapenem resistant K. pneumoniae (CRKP) has become a menace for the treatment with monotherapy of the patients mainly admitted in intensive care units. Hence, in the present study we collected total 187 sputum isolates of K. pneumoniae and performed the antimicrobial susceptibility testing by using the automated Vitek-2 system and broth micro-dilution method (67 CRKP). The combination study of solithromycin with meropenem, colistin, cefotaxime, piperacillin and tazobactam, nitrofurantoin, tetracycline, levofloxacin, curcumin and nalidixic acid was performed by using checkerboard assay. We observed the high rate of resistance towards ampicillin, cefotaxime, ceftriaxone, cefuroxime and aztreonam. The colistin and tigecycline were the most sensitive drugs. The CRKP were 36%, maximum were from the patients of ICUs. The best synergistic effect of solithromycin was with meropenem and cefotaxime (100%), colistin and tetracycline (80%). So, these combinations can be a choice of treatment for the infections caused by MDR CRKP and other Gram-negative bacteria where the monotherapy could not work.
Keyphrases
- klebsiella pneumoniae
- multidrug resistant
- gram negative
- escherichia coli
- acinetobacter baumannii
- drug resistant
- end stage renal disease
- newly diagnosed
- pseudomonas aeruginosa
- chronic kidney disease
- ejection fraction
- intensive care unit
- healthcare
- randomized controlled trial
- cystic fibrosis
- machine learning
- high throughput
- mycobacterium tuberculosis
- open label
- drug delivery
- emergency department
- respiratory tract
- liquid chromatography tandem mass spectrometry
- study protocol
- mass spectrometry
- deep learning
- community acquired pneumonia
- patient reported